Sprout Pharmaceuticals' Addyi® (flibanserin) Named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards

Recognition follows Addyi's newly expanded FDA approval to treat both premenopausal and postmenopausal women under age 65

RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the most trusted and influential honors a brand can receive. 

The Oprah Daily Menopause O-wards shine a light on products that meaningfully improve the lives of women in menopause and midlife. Addyi's recognition reflects its status as a treatment doctors trust and choose more than any other for Hypoactive Sexual Desire Disorder (HSDD), backed by a one-of-a-kind approach to treating low desire and robust clinical proof that earned FDA approval for women under age 65.

"This recognition matters because it finally puts sexual health where it belongs—at the center of the conversation on women's health and longevity," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals. "For too long, women were told to downplay or dismiss changes in desire. Addyi shut down that narrative with clinical proof. Being honored by Oprah Daily reinforces what the science shows and what women deserve to hear: HSDD is common, it's treatable, and it warrants real medical attention."

The honor follows a pivotal moment for women's sexual health: in December 2025, the U.S. Food and Drug Administration expanded Addyi's approval from premenopausal women to include women with HSDD under 65 regardless of peri or post-menopausal status. This approval closed a long-standing gap in care and recognized Addyi's well-established safety and efficacy profile backed by more than a decade of clinical and real-world data.

Regarded as a powerful endorsement among consumers, clinicians, and cultural voices, the Oprah Daily Editor's Choice seal reflects a broader shift toward normalizing conversations about menopause, desire, and women's quality of life—topics long overlooked by medicine and media alike.

"Menopause does not end a woman's sexuality but too often, women are made to feel invisible or untreatable when desire changes. I see it every day in my practice," said Dr. Kelly Casperson, board-certified urologist, sexual health specialist, and bestselling author of The Menopause Moment. "When women are offered real treatment options, they get something priceless back: hope. Addyi gives clinicians a science-backed option for HSDD before or after menopause and opens the door to more honest, informed conversations about sexual health at midlife and beyond.'

Since its FDA approval in 2015, Addyi has remained the #1 prescribed treatment for HSDD*, shaping how women's sexual health is understood and treated across the lifespan. Sprout Pharmaceuticals continues to lead the charge for evidence-based care and long-overdue equity in women's health.

Press Contact:Sunshine Sachs Morgan & Lylis[email protected]

About Sprout Pharmaceuticals

Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first ever FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve.

About Addyi® (flibanserin)

Addyi is the first FDA-approved prescription medication for the treatment of hypoactive sexual desire disorder (HSDD), now including all women under 65. It is a non-hormonal, once-daily pill prescribed by more than 30,000 U.S. healthcare professionals. Addyi works on key neurotransmitters involved in sexual desire and responsiveness.

Addyi is broadly accessible and affordable for most patients: women with insurance typically pay just $40 annually, and for those paying cash, Addyi is available for $149 per month with free shipping through PHILRx mail-order pharmacy. Addyi is also available at more than 70,000 retail pharmacies nationwide, where patients can use a GoodRx coupon to lower out-of-pocket costs.

Patients should consult with their healthcare provider to determine whether Addyi is appropriate for them. Learn more or start a telehealth visit today at Addyi.com.

About Hypoactive Sexual Desire Disorder (HSDD)Hypoactive Sexual Desire Disorder (HSDD), also known as frustrating low libido, is a persistent lack of sexual interest or desire. It is the most common form of sexual dysfunction in women, impacting an estimated 40% of women according to the Mayo Clinic.

INDICATION

ADDYI (flibanserin) is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to:

Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation, or partner.

Limitations of Use:

IMPORTANT SAFETY INFORMATION

Contraindications

Warnings and Precautions

Drug Interactions

Most Common Adverse Reactions

See Full Prescribing Information and Medication Guide, including Boxed Warning regarding hypotension and syncope in certain settings at Addyi.com/pi.

SOURCE: Sprout Pharmaceuticals* IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. Sept 2022–Dec 2025